Bank of America Merrill Lynch Maintains Neutral on Regeneron Pharmaceuticals

Bank of America Merrill Lynch is out with its report today on Regeneron Pharmaceuticals REGN, maintaining Neutral. In its report, Bank of America Merrill Lynch writes, "We rate REGN shares Neutral. Our DCF-derived PO of $58 is based on risk-adjusted revenue projections of the key pipeline products (Eylea, rilonacept, aflibercept, antibody program)." At the time of posting, shares of REGN were trading pre-market at $55.70, down 0.39% from Wednesday's close.